Media coverage about Agile Therapeutics (NASDAQ:AGRX) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agile Therapeutics earned a news impact score of 0.16 on Accern’s scale. Accern also assigned news stories about the specialty pharmaceutical company an impact score of 44.8654274634958 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news stories that may have effected Accern’s scoring:

Agile Therapeutics (NASDAQ AGRX) traded up $0.06 during trading on Friday, reaching $3.28. 259,782 shares of the company’s stock traded hands, compared to its average volume of 1,171,642. The company has a market cap of $110.08, a PE ratio of -3.57 and a beta of 2.01. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.10 and a current ratio of 4.10. Agile Therapeutics has a 52-week low of $1.93 and a 52-week high of $5.60.

Agile Therapeutics (NASDAQ:AGRX) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. equities analysts forecast that Agile Therapeutics will post -0.97 EPS for the current year.

AGRX has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 target price on shares of Agile Therapeutics in a report on Thursday, September 21st. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Agile Therapeutics in a report on Monday, October 2nd. Royal Bank of Canada reaffirmed a “buy” rating and issued a $10.00 target price on shares of Agile Therapeutics in a report on Wednesday, October 18th. Janney Montgomery Scott cut shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, December 22nd. Finally, Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a report on Friday, December 22nd. One research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company. Agile Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $9.20.

WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Agile Therapeutics (AGRX) Share Price” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/01/13/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-agile-therapeutics-agrx-share-price.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Insider Buying and Selling by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.